Leukemia Research Reports, published by Elsevier Advanced Technology, is a prominent open-access journal dedicated to the latest advancements in the field of hematology and oncology. Since its launch in 2012, this journal has been a vital resource for researchers, healthcare professionals, and students aiming to disseminate and access high-quality research articles focused on various aspects of leukemia and related blood disorders. With an impact factor indicative of its significance in the field, Leukemia Research Reports currently holds a Q3 quartile ranking in both Hematology and Oncology, and is included in key databases such as Scopus. The journal not only embraces a commitment to open access, ensuring that research is freely available, but also actively promotes collaborations that strive to enhance our understanding and treatment of leukemia. Based in the United Kingdom, this journal continues to play a crucial role in fostering innovation and knowledge sharing within the medical community.

Cancer Drug Resistance is a premier journal published by OAE PUBLISHING INC, focusing on the critical field of oncology and pharmacology. Since its inception in 2018, the journal has been at the forefront of presenting innovative research aimed at understanding and overcoming drug resistance in cancer therapy. With an impressive impact factor reflected in its Q2 ranking in Cancer Research and a Q1 ranking in Pharmacology (medical) for 2023, Cancer Drug Resistance serves as a vital resource for researchers, clinicians, and students who are dedicated to advancing cancer treatment and improving patient outcomes. The journal's commitment to disseminating high-quality, peer-reviewed articles underscores its importance within the academic and medical communities. While it operates on an open-access model, facilitating widespread distribution and access to crucial research findings, the journal continuously strives to foster dialogue and collaboration among stakeholders in cancer research and pharmacology. Its mission is clear: to shine a light on the evolving challenges and breakthroughs in drug resistance, paving the way for enhanced therapeutic strategies and clinical solutions.

Targeted Oncology is a premier, peer-reviewed journal published by SPRINGER, focusing on the latest advancements in the field of oncology, specifically targeting the development and application of targeted therapies. Since its inception in 2006, this journal has become an essential resource for researchers, healthcare professionals, and students, providing critical insights into innovative cancer treatments and the pharmacological landscape. Recognized for its impactful contributions, Targeted Oncology holds a distinguished Q1 ranking in both Oncology and Pharmacology categories as of 2023, underscoring its influence and relevance in the scientific community. With an impressive Scopus ranking reflecting its strong citation impact, the journal not only disseminates high-quality research but also facilitates knowledge exchange among oncologists and researchers working towards improving patient outcomes. Although not an Open Access journal, Targeted Oncology is committed to advancing cancer research and therapeutic strategies, making it an invaluable addition to the libraries of any institution dedicated to health and wellness.

CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.

The International Journal of Cancer Management is a distinguished publication dedicated to advancing knowledge and research in the fields of cancer management, oncology, pharmacology, and radiology. Published by BRIEFLAND in the Netherlands, this journal serves as a vital resource for researchers, healthcare professionals, and students interested in the latest developments in cancer care and treatment strategies. With an ISSN of 2538-4422 and an E-ISSN of 2538-497X, the journal features a range of peer-reviewed articles that cover diverse aspects of cancer management, reflecting its commitment to high-quality, impactful research. The journal ranks in the Q4 category for Cancer Research and Oncology and Q3 for both Pharmacology and Surgery in 2023, signifying its growing influence in the scientific community. Through its open access format, the International Journal of Cancer Management ensures that critical research findings are accessible to all, promoting collaboration and innovation in the battle against cancer. Researchers looking to share their findings or learn more about current trends will find this journal an invaluable addition to their professional toolkit.

ANNALS OF ONCOLOGY, published by Elsevier, stands as a premier journal in the field of oncology, hematology, and general medicine, with a notable impact factor that underscores its significance in advancing cancer research and clinical practice. Established in 1990, this journal has become a highly respected source of information, consistently ranked in the Q1 category in its respective fields, showcasing its influence and credibility (Rank #4/404 in Oncology and Rank #2/137 in Hematology as per Scopus rankings). With a focus on innovative therapies, clinical trials, and emerging research, ANNALS OF ONCOLOGY serves as an essential resource for researchers, clinicians, and students dedicated to unraveling the complexities of cancer treatment and care. Although offering restricted access options, its impactful studies and discoveries continue to shape the future of oncology.

Lung Cancer Management, published by FUTURE MEDICINE LTD, is a premier academic journal dedicated to the evolving field of oncology and respiratory medicine. With an ISSN of 1758-1966 and an E-ISSN of 1758-1974, this journal offers a platform for the dissemination of cutting-edge research, clinical studies, and expert reviews, all focusing on the latest advances in lung cancer treatment and management. Despite being a relatively new entry since its inception in 2014 and achieving its converged years from 2020 to 2024, it has already established itself in the Q3 quartile for both oncology and pulmonary and respiratory medicine as of 2023, according to category quartiles rankings. With a Scopus ranking of #98 in the category of Pulmonary and Respiratory Medicine and #266 in Oncology, the journal reflects a commitment to quality and relevance in its content. Although it does not offer open access, it remains a crucial resource for researchers, clinicians, and students seeking to stay informed about the latest developments and practical approaches in lung cancer management. The journal is accessible from its base in the United Kingdom, at UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ensuring that it caters to a global audience eager to explore and contribute to this vital field of medicine.

Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.

CURRENT TREATMENT OPTIONS IN ONCOLOGY, published by Springer, is a premier academic journal dedicated to disseminating cutting-edge research and advancements in the field of oncology and pharmacology. With a commendable impact factor and ranked in the Q1 category in both oncology and pharmacology for 2023, this journal positions itself as a leading resource for researchers, healthcare professionals, and students alike, offering insightful reviews and original articles that critically evaluate treatment methodologies and clinical practices. Covering a wide scope of topics from early detection to innovative therapies, it fosters the translation of research findings into clinical applications. With its convergence years spanning from 2000 to 2024, CURRENT TREATMENT OPTIONS IN ONCOLOGY continues to be at the forefront of oncological research, providing a platform for scholars to explore the latest therapeutic options and improve patient outcomes. Highly regarded in the academic community, this journal is essential for anyone looking to stay informed about the dynamic landscape of cancer treatment.